Page 527 - WSAVA2018
P. 527

13. Bell FW, Klausner JS, Hayden DW, Feeney DA, Johnston SD – Clinical and pathological features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970-1987) JAVMA 199:1623-1630, 1991
14. Teske E, Naan EC, van Dijk EM, Van Garderen E, Shcalken JA – Canine prostatic carcinoma: epidemiological evidence of an increased risk in cas- trated dogs. Mol Cell Endocrinol 197: 251-255, 2002
15. Wright PJ, Stelmasiak T, Black D et al. – Medroxyprogesterone acetate and reproductive processes in male dogs. Austr Vet J 55:437-438, 1979
16. Kojima Y, Kawakami S, Shino M – Effects of chlormadinone acetate treatment on canine prostatic hyperplasia. J Japan Vet Med Assoc 50 (12) 725-728, 1997
17. Murakoshi M, Tagawa M, Ikeda R. Atrophic effects of antiandrogen, chlorma- dinone acetate (CMA) on dog prostate with spontaneous benign prostatic hyperplasia. J Toxicol Sci. 2000 Aug;25(3):143-50
18. Court EA, Watson ADJ, Church DB, Emslie DR – Effects of delmadinone ace- tate on pituitary-adrenal function, glucose tolerance and growth hormone in male dogs. Austr Vet J 76(8): 555-560, 1998
19. Beceriklisoy HB, Serhan S. AY, Duygu KAYA, Ali R. AĞAOĞLU, İbrahim KÜÇÜKASLAN, Okan A. AKSOY, Nil ERÜNAL MARAL, Murat FINDIK2, Selim ASLAN - Treatment of hypersexuality and benign prostatic hypertrophy with delmadinone acetate in intact male dogs. Turk. J. Vet. Anim. Sci.2010; 34(1): 25-31
20. Albouy M, Sanquer A, Maynard L, Eun HM. Efficacies of osaterone and delmadinone in the treatment of benign prostatic hyperplasia in dogs. Vet Rec. 2008 Aug 9;163(6):179-83.
21. Tunn U., Senge T., Schenck B., Neumann F. Effects of cyproterone acetate on experimentally induced canine prostatic hyperplasia. Urol. Int., 35: 125- 140, 1980.
22. Li QG1, Hümpel M. Serum protein binding characteristics of cyproterone acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man. J Steroid Biochem. 1990 Feb;35(2):319-26.
23. Minato K, Koizumi N, Honma S, Tsukamoto K, Iwamura S. Pharmacokinetics and biliary excretion of osaterone acetate, a new steroidal antiandrogen, in dogs. Drug Metab Dispos. 2002 Feb;30(2):167-72.
24. Minato K, Honma S, Shinohara Y, Hashimoto T. - Metabolism of osaterone acetate in dogs and humans.Steroids. 2005 Aug;70(9):563-72.
25. Niżański W, Levy X, Ochota M, Pasikowska J. Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update. Reprod Domest Anim. 2014 Jun;49 Suppl 2:8-15. doi: 10.1111/rda.12297.
S. Jayme1
1Global Alliance for Rabies Control, Philippines Office, Sta. Rosa City, Philippines
Rabies vaccination of dogs to protect people: the Global and Asian experience
Dr. Sarah I. Jayme, MVPHMgt
Sta. Rosa City, Philippines;
The global rabies conference in Geneva in December 2015 set the goal of eliminating canine-mediated human rabies by 2030 through the Global Framework for
the Elimination of Dog-Mediated Human Rabies. Five pillars were identified to achieve rabies elimination: S-Socio-cultural; T-Technical; O-Organizational; P-Political; and R-Resources (STOP-R). Two of the key aspects highlighted were the following: importance of strengthening the intersectoral collaboration through the One Health approach (O-Organization); implementation of mass dog vaccination which is the most cost effective intervention to achieve dog-mediated human rabies elimination (T-Technical).Rabies is a neglected tropical disease wherein 59,000 human lives each year are
lost mainly in rural areas of Africa and Asia. It has been controlled in Latin America and Caribbean wherein only 10 deaths were reported due to dog –mediated rabies in 2016 (Haiti and Guatemala). Almost 60% of global human rabies deaths (35,172 human rabies deaths) occur in Asia with India accounting to almost 60% of the deaths in the region. Africa, on the other hand, record a high human rabies deaths of 21, 476 annually (36% global deaths).
Importance of Dog Vaccination in Rabies Control
The economic burden of rabies is immense with USD 8.6 billion loss per year, majority of which is productivity loss due to premature deaths (54%). Although dog vaccination is the most effective way to control rabies, only 2% of the cost is allocated to dog vaccination and population control. It has been proven in Latin America that investing in dog vaccination to achieve 70% coverage for mass dog vaccination to maintain herd immunity against rabies is effective the decreasing dog- mediated human rabies.
Awareness about rabies, dog vaccination and prompt access to post-exposure prophylaxis for bite victims are the key in the control and prevention of dog-mediated human rabies. Although dog vaccination seems to be the most cost-effective and simple method to prevent
Your Singapore, the Tropical Garden City
  26. Iguer Ouada M, Verstegen JP – Effect of finasteride on seminal composition, prostate function and fertility in male dogs. J Reprod Fert 51:139-149, 1997
27. Sirinarumitr K., Johnston SD., Root-Kustritz MV., Johnston GR., Sarkar DK., Memon MA. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. JAVMA, 218(8): 1275-1279, 2001.
28. Frank D, Sharpe N, Scott MC, Mirro E, Hartman B, Haliwell WH – Chronic ef- fects of flutamide in male beagle dogs. Toxicol Pathol 32: (2):243-249, 2004
· Ponglowhapan S, Lohachit C, Swangchanutai T, Trigg TE: 2002. The effect of the GnRH agonist deslorelin on prostatic volume in dogs. Proceedings Congress European Veterinary Society for Small Animal Reproduction, Liege, May 10-12, p 150;
29. Romagnoli S - Deslorelin in Small Animal Andrology. Proceedings, 5th Biannual congress European Veterinary Society Small Animal Reproduction, Budapest 7-9 April 2006, pagg 204-207
· Romagnoli S, Siminica A, Sontas BH, Milani C, Mollo A, Stelletta C
- Semen quality and onset of sterility following administration of a 4.7- mg deslorelin implant in adult male dogs. Reproduction in Domestic Animals 47 (6) 389-392, doi: 10.1111/rda.12058 2012
30. Sontas BH, Milani C, Gelli D D, Mollo A, Ferrari V, Romagnoli S (2009) - Treat- ment of canine benign prostatic hyperplasia with a GnRH agonist, deslorelin: three clinical cases. Proceedings 6th EVSSAR Symposium. Wroclaw, Poland, June 2009, pag. 77

   525   526   527   528   529